Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
AstraZeneca
Mayo Clinic
Neonc Technologies, Inc.
Bristol-Myers Squibb
Aulos Bioscience, Inc.
University of California, Davis
University of California, San Diego
Ocellaris Pharma, Inc.
Bristol-Myers Squibb
University of Pittsburgh
Dragonfly Therapeutics
7 Hills Pharma, LLC
Vyriad, Inc.
GI Innovation, Inc.
A2 Biotherapeutics Inc.
Incyte Corporation
Incyte Corporation
NuCana plc
Shanghai Public Health Clinical Center
University Hospital, Antwerp
Nimbus Therapeutics
Simcha IL-18, Inc.
Salubris Biotherapeutics Inc
NGM Biopharmaceuticals, Inc
GlaxoSmithKline
Eutilex
Novartis
HUYABIO International, LLC.
Rain Oncology Inc
Klus Pharma Inc.
Genmab
4D pharma plc
Western Sydney Local Health District
Nektar Therapeutics
Institut Bergonié
Incyte Corporation
Genocea Biosciences, Inc.
Incyte Corporation
Gilead Sciences
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Eli Lilly and Company
Shenzhen BinDeBio Ltd.
Stanford University
Western Regional Medical Center
Masonic Cancer Center, University of Minnesota
Harbin Medical University
Sun Yat-sen University
Centre Hospitalier Universitaire de Besancon
National Cancer Institute (NCI)